# DESCRIPTION

## FIELD OF THE INVENTION

- define isolated peptide for use as a medicament

## BACKGROUND OF THE INVENTION

- introduce natural killer cells
- motivate importance of natural killer cells
- describe role of natural killer cells in host protection
- summarize HCMV infection model
- describe expansion and adaptation of Ly49H+ NK cells
- introduce NKG2C+ NK cells
- describe characteristics of adaptive NKG2C+ NK cells
- motivate search for HCMV ligand driving expansion of NKG2C+ NK cells
- introduce HLA-E as cognate ligand for NKG2C
- describe effector functions of adaptive NKG2C+ NK cells
- summarize HLA-E stabilization by peptides
- describe UL40-derived peptides and their role in HCMV infection
- motivate investigation of NKG2C recognition of UL40 peptides
- summarize peptide-dependent interaction of CD94/NKG2 receptors with HLA-E
- describe limitations of prior art
- motivate need for strategy to control HCMV infection and leukemia relapse
- describe global health problem of HCMV congenital infection
- motivate need for new cancer immunotherapy targets
- summarize limitations of prior art in expanding and activating NKG2C+ NK cells

## SUMMARY OF THE INVENTION

- introduce technical problem
- state problem to be solved
- provide solution to technical problem
- describe preferred embodiments
- introduce isolated peptide
- describe peptide for use as medicament
- specify peptide length
- describe surprising finding
- explain activation of NKG2C+ NK cells
- describe receptor specific activation
- explain application in disease treatment
- describe unforeseen peptide sequence specificity
- explain differential recognition by NKG2C+ NK cells
- describe complexes formed by HLA-E and peptides
- explain specific activation of CD94/NKG2C
- describe peptides comprised by UL-40 protein
- describe peptides comprised by MHC Class I molecules
- introduce preferred peptide embodiments
- describe peptide for use as medicament
- explain treatment and prevention of medical conditions
- describe expansion and activation of NKG2C+ NK cells
- explain recognition of pathogenic cells
- describe treatment of cancer
- explain identification of cancer cells
- describe determination of HLA-G and HLA-E expression
- introduce further embodiments of peptide use
- describe administration of peptide with adjuvant
- introduce peptides of the present invention
- motivate combination with pro-inflammatory cytokines
- describe check point inhibitors
- motivate combination with check point inhibitors
- describe advantage of combined administration
- motivate combination with activator of CD2
- describe synergistic effect of combined activation
- motivate combination with IFN-alpha
- describe enhanced differential activation
- introduce vector comprising or encoding peptide
- describe viral vectors
- describe cells expressing peptides as vectors
- describe inducible expression of peptides
- introduce nucleic acid molecule operably linked to promoter
- describe recombinant nucleic acid molecule
- motivate use of controllable promoters
- introduce genetically modified virus
- introduce in vitro method for cultivating NKG2C+ NK cells
- describe contacting NK cells with peptide
- describe optional isolation or enrichment of NKG2C+ NK cells
- motivate contacting cells with IL-15, IL-12, and/or IL-18
- describe characterization of isolated population of NKG2C+ NK cells
- describe specific expression pattern and profile of markers
- describe epigenetic DNA demethylation of effector cytokine genes
- introduce isolated population of NKG2C+ NK cells for use as medicament
- introduce genetically modified virus encoding peptide for use as medicament

## DETAILED DESCRIPTION OF THE INVENTION

- incorporate cited documents by reference
- relate invention to isolated peptide for use as medicament
- define peptide structure and composition
- list amino acid sequences of preferred polypeptides
- describe embodiment of polypeptide with specific length
- describe embodiment of polypeptide with specific surrounding sequences
- describe embodiment of polypeptide with sufficient sequence identity
- describe embodiment of modified polypeptide
- define functionally analogous sequences
- describe embodiment of polypeptide with specific sequence identity
- describe method for determining sequence identity
- relate invention to polypeptide derived from UL-40 protein of HCMV
- relate invention to polypeptide derived from signal sequence of MHC class I molecule
- describe preferred length of amino acid sequence
- define sequence homology
- describe protein modifications to polypeptides
- describe substitutions in amino acid sequence
- describe conservative amino acid substitutions
- relate invention to use of peptide as medicament
- describe expansion and/or activation of NKG2C+ natural killer cells
- describe natural killer cells and their function
- describe CD94/NKG2 family of receptors
- describe NKG2 receptors and their function
- describe non-classical MHC glycoproteins class I
- describe HLA-G and its isoforms
- describe HLA-E and its structure
- relate HLA-G and HLA-E to immune system regulation
- describe role of HLA-G in immune tolerance in pregnancy
- describe aberrant induction of HLA-G expression in malignancies
- define signal peptide and its function
- define expansion and/or activation of NKG2C+ NK cells
- describe medical conditions associated with pathogenic cells expressing HLA-E and peptides SEQ ID NO 1 or 2
- motivate use of peptides as medicament to treat medical conditions
- describe role of CD94/NKG2C receptor complex in NKG2C+NK cells
- describe application of peptides in treatment of inflammatory disorders
- describe use of peptides to inhibit reactivation of human cytomegalovirus (HCMV) infections
- describe UL-40 protein of HCMV and its role in immune evasion
- describe expression of UL-40 in HLA-E-positive target cells
- motivate use of peptides to inhibit reactivation of HCMV infections
- describe administration of peptides to increase NKG2C+NK cells in host
- describe application of peptides in treatment of cancer associated with elevated HLA-G expression
- describe detection of HLA-G and HLA-E expression in cancer cells
- describe identification of medical conditions associated with pathogenic cells expressing HLA-E and peptides SEQ ID NO 1 or 2
- define treatment of a tumor
- describe cancer as a group of diseases
- classify cancers into subcategories
- describe leukemias
- describe sarcomas
- describe melanomas
- describe carcinomas
- describe additional cancers
- define tumor
- describe administration of peptides in combination with adjuvants
- describe adjuvants that enhance production of pro-inflammatory cytokines
- describe administration of peptides in combination with pro-inflammatory cytokines
- define adjuvant
- describe immunological adjuvants
- describe pro-inflammatory cytokines
- describe cytokines
- describe immune-response stimulatory cytokines
- describe administration of peptides in combination with checkpoint inhibitors
- describe checkpoint molecules
- describe co-stimulatory checkpoint molecules
- describe co-inhibitory checkpoint molecules
- describe inhibitors of receptors
- describe activators of receptors
- describe checkpoint modulators
- describe application of peptides in treatment of cancer
- describe application of peptides in treatment of inflammatory disorders
- describe application of peptides in treatment of HCMV infections
- summarize invention
- define lymphocyte-stimulating checkpoint modulators
- list co-inhibitory checkpoint molecules
- describe LILRB1
- describe A2AR
- describe B7-H3
- describe B7-H4
- describe BTLA
- describe CTLA-4
- describe IDO
- describe KIR
- describe LAG-3
- describe PD-1
- describe TIM-3
- describe VISTA
- describe TIGIT
- list co-stimulatory checkpoint molecules
- describe administration of peptide in combination with anti-cancer therapy
- list anti-cancer therapies
- describe immunotherapy
- describe gene therapy
- describe viral gene therapy vectors
- describe non-viral gene therapy vectors
- describe nucleic acid molecule encoding a peptide
- introduce genetically modified cells
- express therapeutically effective polypeptides
- describe cell types for expression
- migrate cells to site of NK cells
- administer cells locally or systemically
- introduce peptides in biocompatible matrix
- describe biocompatible matrix materials
- entrap peptides or vectors in matrix
- define pharmaceutical composition
- administer pharmaceutical composition
- define nucleic acid
- define exogenous nucleic acid
- define polypeptide
- describe polypeptide modifications
- describe peptide additions or deletions
- define peptidomimetics
- describe carriers for administration
- describe administration routes
- describe frequency of administration
- define pharmaceutically acceptable carrier
- describe aqueous and non-aqueous carriers
- describe parenteral vehicles
- describe intravenous vehicles
- describe preservatives and additives
- define pharmaceutically acceptable salts
- describe formulation in neutral or salt form
- describe therapeutically effective amount
- describe dosage ranges for polypeptides
- describe dosage ranges for cells
- describe human body weights
- describe dosages of viral gene therapy vector
- define inducible expression
- define treatment of a disease
- define prophylactic administration
- describe combined administration
- define vaccine
- describe vaccine components
- describe sample types
- describe sample sources
- describe sample uses
- conclude sample description

### EXAMPLES

- introduce human subjects
- describe informed consent
- detail PBMC isolation
- describe HCMV-serostatus screening
- introduce patients undergoing allogeneic hematopoietic stem cell transplantation
- describe informed consent for patients
- detail PBMC isolation for patients
- introduce cells and cell lines
- describe K562/HLA-E cell maintenance
- describe RMA-S/HLA-E cell maintenance
- detail RMA-S/HLA-E/LFA-3 cell transfection
- introduce primary human umbilical vein endothelial cells
- describe amplification of UL40-encoded peptide sequences
- detail sequencing and analysis of UL40-encoded peptide sequences
- introduce HLA E surface stabilization
- describe in vitro stimulation of NK cells
- detail cytotoxicity assays
- introduce in vitro culture of NK cells
- describe flow cytometry
- detail expression analysis of HCMV UL40
- generate HCMV mutant viral strains
- construct BAC TB40R-lox-Tet
- insert Cre recombinase sequences
- mutate UL40 region
- reconstitute virus mutants
- produce virus stock
- determine viral titers
- formulate mathematical model of NK cell proliferation
- define model parameters
- compute total cell number
- validate model with experimental data
- design PCR amplicons
- validate methylation profiles using NGS
- isolate DNA from NK cells
- perform bisulfite conversion and PCR
- sequence PCR products
- analyze sequencing data
- prepare RNA libraries for NGS
- sequence RNA libraries
- map reads to human genome
- calculate gene expression
- perform statistical analysis
- determine surface expression of HLA-E
- detect HLA-G transcripts by RT-PCR
- quantify HLA-G isoforms by qRT-PCR
- detect HLA-G protein by flow cytometry
- summarize patient characteristics

### Summary of the Results

- summarize adaptive NKG2C+ NK cells recognition of HCMV peptides

### Example 1: Sequence Variations in HCMV UL40-Encoded Peptides Control the Activation of Adaptive NKG2C+ NK Cells

- describe NKG2C+NK cells in healthy HCMV+ individuals
- analyze UL40-encoded peptide sequences
- test peptide recognition by adaptive NKG2C+NK cells
- demonstrate differential activation of NKG2C+NK cells
- show peptide recognition is independent of HLA-E binding
- analyze peptide recognition at sub-optimal concentrations
- demonstrate specific receptor-mediated recognition
- compare NKG2C+ and NKG2A+ cell responses
- summarize data on HCMV peptide recognition

### Example 2: Co-Stimulatory Signals are Required to Elicit Polyfunctionality of Adaptive NKG2C+NK Cells Upon Engagement with Sub-Optimal Peptides

- examine co-stimulation of adaptive NKG2C+NK cells
- demonstrate CD2 co-stimulation enhances peptide recognition

### Example 3: Adaptive NKG2C+NK Cells Differentially Recognize HCMV-Encoded Peptides During Infection

- generate HCMV strains with modified UL40 loci
- infect primary human cells with modified HCMV strains
- demonstrate differential recognition of HCMV peptides

### Example 4: Peptide Recognition Controls Relative Accumulation of NKG2C+NK Cells from HCMV− Individuals in the Presence of Pro-Inflammatory Signals

- examine peptide recognition by NKG2C+NK cells from HCMV− individuals
- demonstrate peptide-dependent proliferation of NKG2C+NK cells
- show co-stimulation enhances peptide recognition
- analyze NKG2C+NK cell proliferation dynamics
- model NKG2C+NK cell proliferation and accumulation
- demonstrate accelerated cell division and death rates
- summarize data on peptide recognition and NKG2C+NK cell accumulation

### Example 5: Peptide Recognition and Pro-Inflammatory Cytokines Co-Operate in Guiding the Differentiation of Adaptive NKG2C+ NK Cells

- examine peptide recognition and pro-inflammatory cytokines
- demonstrate co-operation in guiding NKG2C+NK cell differentiation
- analyze receptor repertoire and epigenetic landscape
- show down-regulation of FcεR1γ and CD7
- demonstrate DNA methylation reduction
- analyze global transcriptional imprinting
- show sustained up-regulation of activation and exhaustion markers
- demonstrate effector function up-regulation
- summarize data on peptide recognition and NKG2C+NK cell differentiation

### Discussion of Examples 1-5

- discuss HCMV-induced adaptive NKG2C+NK cells
- describe features of NKG2C+NK cells
- propose expression of NKG2C as adaptive feature
- discuss UL40-encoded peptides
- suggest immune evasion strategy by HCMV
- analyze peptides unable to stabilize HLA-E
- discuss UL40 polymorphisms and NKG2C-mediated responses
- propose immune pressure mediated by adaptive NKG2C+NK cells
- discuss commonly represented HCMV UL40 peptides
- compare UL40 peptides to self-peptides derived from HLA class I alleles
- envision activation of adaptive NKG2C+NK cells
- discuss rare UL40-derived VMAPRTLFL peptide
- analyze structural analyses of CD94/NKG2 heterodimers
- imply differential functional consequences of CD94/NKG2A and CD94/NKG2C engagement
- discuss conformational changes affecting recognition of HLA-E-bound peptides
- discuss pivotal role of NKG2C in activating NK cells
- mention case report suggesting NKG2C+NK cells control HCMV infection
- discuss individuals deficient for KLRC2
- imply presence of compensatory mechanisms
- discuss adaptive NKG2C− NK cells expressing activating KIR
- conclude mechanism of specific innate recognition of HCMV-infected cells

